Lucentis (Ranibizumab) in Diabetic Macular Oedema: a Treatment Evaluation

Inclusion Criteria: * Diagnosis of diabetes mellitus (type 1 or type 2) * Retinal thickening due to diabetic macular oedema involving the centre of the macula and OCT central subfield ≥ 300 microns * Best corrected visual acuity in the study eye between 55 and 79 ETDRS letters at 1 metre (Snellen equivalent ≥ 6/24 and ≤ 6/9) * Media clarity, pupillary dilation, and subject cooperation sufficient for adequate fundus photographs * Intraocular pressure less than 30 mmHg * Ability to return for study visits * Visual acuity in fellow eye ≥ 2/60 * Fellow eye has received no anti-VEGF treatment within the past 3 months and no expectation of such treatment in next 12 months * No previous laser within 3 months of randomisation * Ability to give informed consent throughout the duration of the study Exclusion Criteria: * Macular ischaemia * Macular oedema from a cause other than diabetic macular oedema * Co-existent ocular disease * Presence of an ocular condition such that visual acuity would not improve from resolution of macular oedema * Presence of an ocular condition that might affect macular oedema or alter visual acuity during the course of the study * A substantial cataract that is likely to be decreasing visual acuity by 3 lines or more * History of treatment for diabetic macular oedema at any time in the past 3 months * History of panretinal scatter photocoagulation (PRP) within 3 months prior to randomisation * Anticipated need for PRP in the 6 months following randomisati…